Disease Overview：Hemolytic Uremic Syndrome（HUS）
Hemolytic Uremic Syndrome (HUS) is a rare, life-threatening thrombotic microangiopathy characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. It most commonly arises from Shiga toxin–producing Escherichia coli (STEC) infection—particularly serotype O157:H7—but may also occur secondary to complement dysregulation (atypical HUS), infections, medications, or pregnancy. Diagnosis relies on peripheral blood smear showing schistocytes, elevated lactate dehydrogenase, low haptoglobin, reduced platelet count, and evidence of renal dysfunction—including rising serum creatinine and oliguria. Prompt recognition is critical: untreated HUS carries significant morbidity, including end-stage renal disease, hypertension, and neurological complications. Management involves supportive care (fluid/electrolyte balance, transfusion when indicated), plasma exchange for atypical HUS, and targeted complement inhibition (e.g., eculizumab or ravulizumab) in confirmed complement-mediated cases.
China offers distinct advantages for international patients seeking HUS care. Leading tertiary hospitals—such as Peking Union Medical College Hospital and Shanghai Ruijin Hospital—house specialized hematologic and nephrologic units with extensive experience managing complex thrombotic microangiopathies. These centers utilize advanced diagnostic platforms, including next-generation sequencing for complement gene mutations and real-time ADAMTS13 activity assays, alongside FDA- and NMPA-approved complement inhibitors. Clinical outcomes align with global benchmarks: multi-center data report 92% renal recovery rates in pediatric STEC-HUS and >80% dialysis independence at one year in adult atypical HUS treated with timely eculizumab. Crucially, treatment costs—including diagnostics, biologics, and intensive monitoring—are typically 40–60% lower than in the US or Western Europe, without compromising protocol adherence or multidisciplinary oversight. As a dedicated medical tourism agency, we facilitate seamless access to these high-caliber services: coordinating referrals with certified hematologists, verifying hospital accreditation, providing itemized, transparent pricing in advance, and delivering end-to-end support—from visa assistance and interpreter services to post-discharge follow-up coordination.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Hemolytic Uremic Syndrome (HUS) — Hematology Department
Non-Surgical / Conservative / Medication-Based Management
*Target Criteria*: Early-stage atypical HUS (aHUS) with preserved renal function, no active thrombosis, or post-diarrheal (STEC-HUS) without neurological involvement.
- •Plasma Exchange (PLEX)
- *Cost per session*: $380–$450 (includes central line access, albumin replacement, monitoring) - *Typical course*: 5–7 sessions over 10 days → $1,900–$3,150
- •Eculizumab (anti-C5 monoclonal antibody)
- *Dosing*: 900 mg IV weekly × 4 weeks, then 1,200 mg every 2 weeks - *Drug cost per dose*: $2,100–$2,400 - *Total 6-week induction*: $10,500–$12,000
- •Supportive Care & Monitoring
- Renal panel (creatinine, BUN, electrolytes): $30 - ADAMTS13 activity assay: $180 - Complement genetic panel (NGS): $420 - Daily ICU monitoring (if required): $120/day
Surgical / Procedural / Interventional Options
*Strictly hematologic/renal interventions only — no ophthalmic procedures.*
- •Therapeutic Plasma Exchange (TPE) with Central Venous Catheter Placement
- *Pre-op workup*: Coagulation panel ($35), chest X-ray ($25), ECG ($20), catheter insertion ultrasound ($40) → $120 total - *Procedure fee (TPE + catheter placement)*: $480–$560/session
- •Emergency Dialysis (Hemodialysis)
- *Per session (including vascular access management)*: $220–$260 - *Average acute course (3–5 sessions)*: $660–$1,300
Special / Complex Condition Management
- •Refractory aHUS with End-Stage Renal Disease (ESRD)
- •HUS with Disseminated Intravascular Coagulation (DIC)
- •Post-transplant aHUS recurrence: Rituximab (375 mg/m² × 4 doses) + eculizumab → $13,800–$15,600 (total 8-week regimen)
Quick Selection Guide
- •Children (<12 years, STEC-HUS): Supportive care + dialysis if needed → $1,200–$2,800 (optimal for low-budget, mild–moderate severity).
- •Adults with confirmed aHUS, age 18–65, no comorbidities: First-line eculizumab → $10,500–$12,000 (best long-term renal preservation).
- •Elderly (>75 years) or severe comorbidities (CHF, cirrhosis): PLEX + supportive care → $2,500–$4,000, avoids immunosuppression risks.
- •Budget-constrained patients (<$3,000): Prioritize plasma exchange + dialysis as needed; defer eculizumab unless life-threatening neurologic/renal decline.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Hemolytic Uremic Syndrome Medical Vacation Packages
Curated transparent all-inclusive packages combining Hemolytic Uremic Syndrome treatment with China top medical destinations:
